Comment
doi: 10.1016/S1470-2045(13)70582-5.
Epub 2013 Dec 11.
Evidence-based treatment for low-risk basal cell carcinoma
Affiliations
- PMID: 24332515
- DOI: 10.1016/S1470-2045(13)70582-5
Item in Clipboard
Comment
Evidence-based treatment for low-risk basal cell carcinoma
Lancet Oncol.
2014 Jan.
No abstract available
Comment on
-
Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial.Lancet Oncol. 2014 Jan;15(1):96-105. doi: 10.1016/S1470-2045(13)70530-8. Epub 2013 Dec 11. Lancet Oncol. 2014. PMID: 24332516 Clinical Trial.
Similar articles
-
Basal-cell carcinoma: no response versus relapse.Lancet Oncol. 2014 Mar;15(3):e104-5. doi: 10.1016/S1470-2045(14)70014-2. Lancet Oncol. 2014. PMID: 24599926 No abstract available.
-
[Evidence-based medicine: Analysis of the randomized trial "imiquimod vs. surgery for basal cell carcinoma"].Ann Dermatol Venereol. 2015 May;142(5):369-70. doi: 10.1016/j.annder.2015.01.008. Epub 2015 Mar 3. Ann Dermatol Venereol. 2015. PMID: 25749512 French. No abstract available.
-
Basal-cell carcinoma: no response versus relapse - author's reply.Lancet Oncol. 2014 Mar;15(3):e105. doi: 10.1016/S1470-2045(14)70068-3. Lancet Oncol. 2014. PMID: 24599928 No abstract available.
-
New perspectives in the management of basal cell carcinoma.Actas Dermosifiliogr. 2014 Nov;105(9):874-5. doi: 10.1016/j.ad.2014.04.007. Epub 2014 Jun 14. Actas Dermosifiliogr. 2014. PMID: 24934656 Review. English, Spanish. No abstract available.
-
Topical treatment of basal cell carcinoma with the immune response modifier imiquimod.Future Oncol. 2015 Nov;11(22):2985-90. doi: 10.2217/fon.15.192. Epub 2015 Oct 9. Future Oncol. 2015. PMID: 26450707 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
